These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 21821712

  • 21. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
    Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.
    Clin Cancer Res; 2013 Nov 15; 19(22):6313-21. PubMed ID: 24097860
    [Abstract] [Full Text] [Related]

  • 22. The pharmacological management of hairy cell leukemia.
    Ramos Perez J, Ravandi-Kashani F.
    Expert Opin Pharmacother; 2020 Aug 15; 21(11):1337-1344. PubMed ID: 32378970
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Treatment Outcomes Of Patients With Hairy Cell Leukaemia; A 16-Year Experience At A Tertiary Care Center In Pakistan.
    Yousaf M, Khan MA, Iftikhar R, Chaudary QU, Shahbaz N, Ahmad U, Javed H.
    J Ayub Med Coll Abbottabad; 2022 Aug 15; 34(4):797-801. PubMed ID: 36566402
    [Abstract] [Full Text] [Related]

  • 25. Cryptococcal meningitis occurring at 19 months after cladribine therapy for hairy cell leukemia.
    Ikpeazu EV, Kaplon MK.
    Eur J Haematol; 1998 Oct 15; 61(4):286-7. PubMed ID: 9820640
    [No Abstract] [Full Text] [Related]

  • 26. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
    Goodman GR, Burian C, Koziol JA, Saven A.
    J Clin Oncol; 2003 Mar 01; 21(5):891-6. PubMed ID: 12610190
    [Abstract] [Full Text] [Related]

  • 27. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V.
    Leukemia; 2004 Sep 01; 18(9):1476-81. PubMed ID: 15229616
    [Abstract] [Full Text] [Related]

  • 28. COVID-19 in patients with classic and variant hairy cell leukemia.
    Kreitman RJ, Yu T, James L, Feurtado J, Eager H, Ortiz OS, Gould M, Mauter J, Zhou H, Burbelo PD, Cohen JI, Wang HW, Yuan CM, Arons E.
    Blood Adv; 2023 Dec 12; 7(23):7161-7168. PubMed ID: 37729613
    [Abstract] [Full Text] [Related]

  • 29. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant.
    Imamura T, Ohtsuka E, Ogata M, Oka F, Kashima K, Kikuchi H, Nasu M.
    Int J Hematol; 2004 Dec 12; 80(5):432-4. PubMed ID: 15646655
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Successful treatment of refractory hairy cell leukemia with rituximab].
    Onaka T, Ozumi N, Yonezawa A, Imada K.
    Nihon Naika Gakkai Zasshi; 2009 Aug 10; 98(8):1987-9. PubMed ID: 19764485
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.
    Dearden CE, Else M, Catovsky D.
    Leuk Lymphoma; 2011 Jun 10; 52 Suppl 2():21-4. PubMed ID: 21599603
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
    Hacioglu S, Bilen Y, Eser A, Sivgin S, Gurkan E, Yildirim R, Aydogdu I, Dogu MH, Yilmaz M, Kayikci O, Tombak A, Kuku I, Celebi H, Akay MO, Esen R, Korkmaz S, Keskin A.
    Hematol Oncol; 2015 Dec 10; 33(4):192-8. PubMed ID: 25393847
    [Abstract] [Full Text] [Related]

  • 36. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Bastie JN, Cazals-Hatem D, Daniel MT, D'Agay MF, Rabian C, Glaisner S, Noel-Walter MP, Dabout D, Flandrin G, Dombret H, Poisson D, Degos L, Castaigne S.
    Leuk Lymphoma; 1999 Nov 10; 35(5-6):555-65. PubMed ID: 10609793
    [Abstract] [Full Text] [Related]

  • 37. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
    Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, Baur A, Kurrer M, Von Rohr A, Hsu-Schmitz SF, Wagner B, Delacretaz F, Hurwitz N, Swiss Group for Clinical Cancer Research (SAKK).
    Arch Pathol Lab Med; 2006 Mar 10; 130(3):374-7. PubMed ID: 16519567
    [Abstract] [Full Text] [Related]

  • 38. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
    Tallman MS.
    Leuk Lymphoma; 2011 Jun 10; 52 Suppl 2():65-8. PubMed ID: 21463116
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.